Global Gastric Cancer Treatment Market - 2025-2033
Overview
The global gastric cancer treatment market size reached US$ 5.82 billion in 2024 and is expected to reach US$ 14.66 billion by 2033, growing at a CAGR of 10.9% during the forecast period 2025-2033.
Gastric cancer, also known as stomach cancer, refers to a type of cancer that begins in the cells lining the stomach. It is one of the most common and deadly forms of cancer worldwide, particularly prevalent in East Asia, Europe, and parts of South America. Gastric cancer can develop in any part of the stomach and may spread to other organs, such as the esophagus, pancreas, liver, and lymph nodes.
Gastric cancer primarily originates from the epithelial cells that line the stomach, leading to adenocarcinoma, which is the most common type of gastric cancer (around 90-95% of cases). However, gastric cancer can also include other, rarer forms such as lymphoma (cancer of lymphatic tissue), gastrointestinal stromal tumors (GISTs), and neuroendocrine tumors.
Market Dynamics: Drivers & Restraints
Rising advancements in targeted therapies are significantly driving the gastric cancer treatment market growth
One of the most notable advancements in gastric cancer treatment has been the development of HER2-targeted therapies. HER2 (human epidermal growth factor receptor 2) is a protein overexpressed in some gastric cancer cells, leading to uncontrolled cell growth. Trastuzumab (Herceptin), a monoclonal antibody targeting HER2, has been a groundbreaking treatment for HER2-positive gastric cancer. The success of this treatment has led to its widespread use in combination with chemotherapy for advanced gastric cancer.
For instance, in October 2024, Astellas Pharma Inc. announced that the U.S. Food and Drug Administration (FDA) approved VYLOY (zolbetuximab-clzb) in combination with fluoropyrimidine- and platinum-containing chemotherapy for the first-line treatment of adults with locally advanced unresectable or metastatic human epidermal growth factor receptor 2 (HER2)-negative gastric or gastroesophageal junction (GEJ) adenocarcinoma whose tumors are claudin (CLDN) 18.2 positive as determined by an FDA-approved test. VYLOY is the first and only CLDN18.2-targeted therapy approved in the U.S.
The rising advancements in targeted therapies have been a significant driver for the growth of the gastric cancer treatment market. The shift towards more personalized and effective treatments, combined with the FDA approvals of new drugs, the growing market acceptance, and the increased survival rates in patients, all contribute to this growth. As the research in this field continues to progress, it is expected that targeted therapies will become even more refined, offering greater hope for gastric cancer patients and expanding the market further.
Side effects and safety concerns associated with the treatment are hampering the market growth
Despite the significant advancements in gastric cancer treatment, side effects and safety concerns continue to pose major challenges in the management of the disease. The adverse effects associated with both traditional and targeted therapies often deter patients from adhering to prescribed regimens, impact their quality of life, and complicate treatment regimens. These concerns, in turn, hinder the widespread adoption and growth of the gastric cancer treatment market.
Chemotherapy remains a cornerstone of treatment for gastric cancer, but it is associated with a range of severe side effects. These can lead to dose reductions, discontinuation of therapy, and decreased quality of life, which ultimately hampers market growth. While targeted therapies and immunotherapies have revolutionized gastric cancer treatment, these therapies are not without their risks. Although they tend to have fewer side effects than chemotherapy, they can still cause severe immune-related adverse events (irAEs) or off-target effects.
Epidemiology Analysis
The incidence of gastric cancer is rising. As per DataM intelligence estimates, nearly 1.02 million prevalent cases are estimated worldwide in 2024. The region with the highest prevalence is the Asia-Pacific, accounting for 190.28 million cases. Early detection through screening, better treatment options, and improved public health measures have contributed to the decline in incidence and mortality rates in developed countries. However, gastric cancer continues to present a major healthcare burden, particularly in developing nations and among high-risk populations.
Pipeline Analysis
Top Phase III Pipeline Products for Gastric Cancer:
Segment Analysis
The global gastric cancer treatment market is segmented based on cancer type, treatment type, route of administration, and region.
Treatment Type:
The chemotherapy segment is expected to dominate the gastric cancer treatment market with the highest market share
Chemotherapy is frequently used as the primary treatment in advanced gastric cancer, often in combination with targeted therapies or immunotherapy. In cases where surgery is not possible, chemotherapy serves as a crucial palliative treatment to control symptoms, slow the disease’s progression, and improve survival rates. For instance, FOLFOX (a combination of 5-fluorouracil (5-FU), oxaliplatin, and leucovorin) is a standard chemotherapy regimen used in gastric cancer. This regimen is particularly effective for advanced gastric cancer and has been widely adopted.
Chemotherapy is frequently combined with targeted therapies like trastuzumab, ramucirumab, and nivolumab to enhance efficacy, especially in advanced or metastatic gastric cancer. These combination regimens have become the standard of care in many treatment protocols. The growing trend of combining chemotherapy with newer therapies has expanded its market dominance, as it remains the central component of first-line and second-line treatment regimens in both HER2-positive and HER2-negative gastric cancers.
Geographical Analysis
North America is expected to hold a significant position in the global gastric cancer treatment market with the highest market share
The FDA (U.S. Food and Drug Administration) and Health Canada are at the forefront of regulatory approvals for new cancer therapies, including those for gastric cancer. These agencies have fast-tracked and drug approvals for novel treatments like TEVIMBRA (tislelizumab-jsgr), nivolumab (Opdivo), trastuzumab (Herceptin), and ramucirumab (Cyramza). This further accelerates the market growth in the region with various effective treatments.
For instance, in December 2024, BeiGene, Ltd., a global oncology company that intends to change its name to BeOne Medicines Ltd., announced the U.S. Food and Drug Administration (FDA) approved TEVIMBRA (tislelizumab-jsgr), in combination with platinum and fluoropyrimidine-based chemotherapy, for the first-line treatment of unresectable or metastatic HER2-negative gastric or gastroesophageal junction adenocarcinoma (G/GEJ) in adults whose tumors express PD-L1 (?1).
North America has been a leader in adopting targeted therapies and immunotherapies, which are increasingly used to treat gastric cancer. The region's healthcare system supports the use of expensive, but highly effective, biologics and immunotherapy drugs that target specific proteins or immune checkpoints involved in cancer progression. For instance, Trastuzumab (Herceptin) is widely used for HER2-positive gastric cancer, and its combination with chemotherapy has led to better survival rates. Nivolumab (Opdivo), an immune checkpoint inhibitor, is also approved for use in gastric cancer and has been shown to significantly improve survival in combination with chemotherapy.
Competitive Landscape
Top companies in the gastric cancer treatment market include Merck & Co., Inc., Eli Lilly and Company, Genentech USA, Inc., Pfizer Inc., Astellas Pharma Inc., Bristol-Myers Squibb Company, Blueprint Medicines Corporation, Daiichi Sankyo, Inc., BeiGene, Ltd., Ipsen Biopharmaceuticals Inc., Taiho Oncology, Inc., and Deciphera Pharmaceuticals, LLC., and among others.
Why Purchase the Report?
Target Audience 2024
The global gastric cancer treatment market size reached US$ 5.82 billion in 2024 and is expected to reach US$ 14.66 billion by 2033, growing at a CAGR of 10.9% during the forecast period 2025-2033.
Gastric cancer, also known as stomach cancer, refers to a type of cancer that begins in the cells lining the stomach. It is one of the most common and deadly forms of cancer worldwide, particularly prevalent in East Asia, Europe, and parts of South America. Gastric cancer can develop in any part of the stomach and may spread to other organs, such as the esophagus, pancreas, liver, and lymph nodes.
Gastric cancer primarily originates from the epithelial cells that line the stomach, leading to adenocarcinoma, which is the most common type of gastric cancer (around 90-95% of cases). However, gastric cancer can also include other, rarer forms such as lymphoma (cancer of lymphatic tissue), gastrointestinal stromal tumors (GISTs), and neuroendocrine tumors.
Market Dynamics: Drivers & Restraints
Rising advancements in targeted therapies are significantly driving the gastric cancer treatment market growth
One of the most notable advancements in gastric cancer treatment has been the development of HER2-targeted therapies. HER2 (human epidermal growth factor receptor 2) is a protein overexpressed in some gastric cancer cells, leading to uncontrolled cell growth. Trastuzumab (Herceptin), a monoclonal antibody targeting HER2, has been a groundbreaking treatment for HER2-positive gastric cancer. The success of this treatment has led to its widespread use in combination with chemotherapy for advanced gastric cancer.
For instance, in October 2024, Astellas Pharma Inc. announced that the U.S. Food and Drug Administration (FDA) approved VYLOY (zolbetuximab-clzb) in combination with fluoropyrimidine- and platinum-containing chemotherapy for the first-line treatment of adults with locally advanced unresectable or metastatic human epidermal growth factor receptor 2 (HER2)-negative gastric or gastroesophageal junction (GEJ) adenocarcinoma whose tumors are claudin (CLDN) 18.2 positive as determined by an FDA-approved test. VYLOY is the first and only CLDN18.2-targeted therapy approved in the U.S.
The rising advancements in targeted therapies have been a significant driver for the growth of the gastric cancer treatment market. The shift towards more personalized and effective treatments, combined with the FDA approvals of new drugs, the growing market acceptance, and the increased survival rates in patients, all contribute to this growth. As the research in this field continues to progress, it is expected that targeted therapies will become even more refined, offering greater hope for gastric cancer patients and expanding the market further.
Side effects and safety concerns associated with the treatment are hampering the market growth
Despite the significant advancements in gastric cancer treatment, side effects and safety concerns continue to pose major challenges in the management of the disease. The adverse effects associated with both traditional and targeted therapies often deter patients from adhering to prescribed regimens, impact their quality of life, and complicate treatment regimens. These concerns, in turn, hinder the widespread adoption and growth of the gastric cancer treatment market.
Chemotherapy remains a cornerstone of treatment for gastric cancer, but it is associated with a range of severe side effects. These can lead to dose reductions, discontinuation of therapy, and decreased quality of life, which ultimately hampers market growth. While targeted therapies and immunotherapies have revolutionized gastric cancer treatment, these therapies are not without their risks. Although they tend to have fewer side effects than chemotherapy, they can still cause severe immune-related adverse events (irAEs) or off-target effects.
Epidemiology Analysis
The incidence of gastric cancer is rising. As per DataM intelligence estimates, nearly 1.02 million prevalent cases are estimated worldwide in 2024. The region with the highest prevalence is the Asia-Pacific, accounting for 190.28 million cases. Early detection through screening, better treatment options, and improved public health measures have contributed to the decline in incidence and mortality rates in developed countries. However, gastric cancer continues to present a major healthcare burden, particularly in developing nations and among high-risk populations.
Pipeline Analysis
Top Phase III Pipeline Products for Gastric Cancer:
Segment Analysis
The global gastric cancer treatment market is segmented based on cancer type, treatment type, route of administration, and region.
Treatment Type:
The chemotherapy segment is expected to dominate the gastric cancer treatment market with the highest market share
Chemotherapy is frequently used as the primary treatment in advanced gastric cancer, often in combination with targeted therapies or immunotherapy. In cases where surgery is not possible, chemotherapy serves as a crucial palliative treatment to control symptoms, slow the disease’s progression, and improve survival rates. For instance, FOLFOX (a combination of 5-fluorouracil (5-FU), oxaliplatin, and leucovorin) is a standard chemotherapy regimen used in gastric cancer. This regimen is particularly effective for advanced gastric cancer and has been widely adopted.
Chemotherapy is frequently combined with targeted therapies like trastuzumab, ramucirumab, and nivolumab to enhance efficacy, especially in advanced or metastatic gastric cancer. These combination regimens have become the standard of care in many treatment protocols. The growing trend of combining chemotherapy with newer therapies has expanded its market dominance, as it remains the central component of first-line and second-line treatment regimens in both HER2-positive and HER2-negative gastric cancers.
Geographical Analysis
North America is expected to hold a significant position in the global gastric cancer treatment market with the highest market share
The FDA (U.S. Food and Drug Administration) and Health Canada are at the forefront of regulatory approvals for new cancer therapies, including those for gastric cancer. These agencies have fast-tracked and drug approvals for novel treatments like TEVIMBRA (tislelizumab-jsgr), nivolumab (Opdivo), trastuzumab (Herceptin), and ramucirumab (Cyramza). This further accelerates the market growth in the region with various effective treatments.
For instance, in December 2024, BeiGene, Ltd., a global oncology company that intends to change its name to BeOne Medicines Ltd., announced the U.S. Food and Drug Administration (FDA) approved TEVIMBRA (tislelizumab-jsgr), in combination with platinum and fluoropyrimidine-based chemotherapy, for the first-line treatment of unresectable or metastatic HER2-negative gastric or gastroesophageal junction adenocarcinoma (G/GEJ) in adults whose tumors express PD-L1 (?1).
North America has been a leader in adopting targeted therapies and immunotherapies, which are increasingly used to treat gastric cancer. The region's healthcare system supports the use of expensive, but highly effective, biologics and immunotherapy drugs that target specific proteins or immune checkpoints involved in cancer progression. For instance, Trastuzumab (Herceptin) is widely used for HER2-positive gastric cancer, and its combination with chemotherapy has led to better survival rates. Nivolumab (Opdivo), an immune checkpoint inhibitor, is also approved for use in gastric cancer and has been shown to significantly improve survival in combination with chemotherapy.
Competitive Landscape
Top companies in the gastric cancer treatment market include Merck & Co., Inc., Eli Lilly and Company, Genentech USA, Inc., Pfizer Inc., Astellas Pharma Inc., Bristol-Myers Squibb Company, Blueprint Medicines Corporation, Daiichi Sankyo, Inc., BeiGene, Ltd., Ipsen Biopharmaceuticals Inc., Taiho Oncology, Inc., and Deciphera Pharmaceuticals, LLC., and among others.
Why Purchase the Report?
- Pipeline & Innovations: Reviews ongoing clinical trials, product pipelines, and forecasts upcoming advancements in medical devices and pharmaceuticals.
- Product Performance & Market Positioning: Analyze product performance, market positioning, and growth potential to optimize strategies.
- Real-World Evidence: Integrates patient feedback and data into product development for improved outcomes.
- Physician Preferences & Health System Impact: Examines healthcare provider behaviors and the impact of health system mergers on adoption strategies.
- Market Updates & Industry Changes: Covers recent regulatory changes, new policies, and emerging technologies.
- Competitive Strategies: Analyzes competitor strategies, market share, and emerging players.
- Pricing & Market Access: Reviews pricing models, reimbursement trends, and market access strategies.
- Market Entry & Expansion: Identifies optimal strategies for entering new markets and partnerships.
- Regional Growth & Investment: Highlights high-growth regions and investment opportunities.
- Supply Chain Optimization: Assesses supply chain risks and distribution strategies for efficient product delivery.
- Sustainability & Regulatory Impact: Focuses on eco-friendly practices and evolving regulations in healthcare.
- Post-market Surveillance: Uses post-market data to enhance product safety and access.
- Pharmacoeconomics & Value-Based Pricing: Analyzes the shift to value-based pricing and data-driven decision-making in R&D.
Target Audience 2024
- Manufacturers: Pharmaceutical, Medical Device, Biotech Companies, Contract Manufacturers, Distributors, Hospitals.
- Regulatory & Policy: Compliance Officers, Government, Health Economists, Market Access Specialists.
- Technology & Innovation: AI/Robotics Providers, R&D Professionals, Clinical Trial Managers, Pharmacovigilance Experts.
- Investors: Healthcare Investors, Venture Fund Investors, Pharma Marketing & Sales.
- Consulting & Advisory: Healthcare Consultants, Industry Associations, Analysts.
- Supply Chain: Distribution and Supply Chain Managers.
- Consumers & Advocacy: Patients, Advocacy Groups, Insurance Companies.
- Academic & Research: Academic Institutions.
1. MARKET INTRODUCTION AND SCOPE
1.1. Objectives of the Report
1.2. Report Coverage & Definitions
1.3. Report Scope
2. EXECUTIVE INSIGHTS AND KEY TAKEAWAYS
2.1. Market Highlights and Strategic Takeaways
2.2. Key Trends and Future Projections
2.3. Snippet by Cancer Type
2.4. Snippet by Treatment Type
2.5. Snippet by Route of Administration
2.6. Snippet by Region
3. DYNAMICS
3.1. Impacting Factors
3.1.1. Drivers
3.1.1.1. Advancements in Targeted Therapies
3.1.1.2. Expanding Clinical Trials and Research Investment
3.1.1.3. XX
3.1.2. Restraints
3.1.2.1. Side Effects and Safety Concerns
3.1.2.2. High Treatment Costs
3.1.2.3. XX
3.1.3. Opportunity
3.1.3.1. Advancements in Treatment Options
3.1.3.2. XX
3.1.4. Impact Analysis
4. STRATEGIC INSIGHTS AND INDUSTRY OUTLOOK
4.1. Market Leaders and Pioneers
4.1.1. Emerging Pioneers and Prominent Players
4.1.2. Established Leaders with Largest Marketing Brand
4.1.3. Market Leaders with Established Products
4.2. Latest Developments and Breakthroughs
4.3. Regulatory and Reimbursement Landscape
4.3.1. North America
4.3.2. Europe
4.3.3. Asia Pacific
4.3.4. Latin America
4.3.5. Middle East & Africa
4.4. Porter’s Five Forces Analysis
4.5. Supply Chain Analysis
4.6. Patent Analysis
4.7. SWOT Analysis
4.8. Pipeline Analysis
4.9. Epidemiology Analysis
4.10. Unmet Needs and Gaps
4.11. Recommended Strategies for Market Entry and Expansion
4.12. Scenario Analysis: Best-Case, Base-Case, and Worst-Case Forecasts
4.13. Pricing Analysis and Price Dynamics
4.14. Key Opinion Leaders
5. GASTRIC CANCER TREATMENT MARKET, BY CANCER TYPE
5.1. Introduction
5.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
5.1.2. Market Attractiveness Index, By Cancer Type
5.2. Non-Cardia (Distal) Stomach Cancer*
5.2.1. Introduction
5.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
5.3. Proximal Stomach Cancer
5.4. Diffuse Stomach Cancer
5.5. Lymphomas
5.6. Gastrointestinal Stromal Tumors
5.7. Carcinoid Tumors
5.8. Adenocarcinoma
5.9. Others
6. GASTRIC CANCER TREATMENT MARKET, BY TREATMENT TYPE
6.1. Introduction
6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
6.1.2. Market Attractiveness Index, By Treatment Type
6.2. Chemotherapy*
6.2.1. Introduction
6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
6.2.3. Capecitabine
6.2.4. Cisplatin
6.2.5. Docetaxel
6.2.6. Doxorubicin
6.2.7. Epirubicin
6.2.8. Fluorouracil (5-FU)
6.2.9. Irinotecan
6.2.10. Leucovorin
6.2.11. Oxaliplatin
6.2.12. Paclitaxel
6.2.13. Others
6.3. Radiation Therapy
6.4. Targeted Therapy
6.4.1. Ramucirumab
6.4.2. Regorafenib
6.4.3. Trastuzumab
6.4.4. Zolbetuximab
6.4.5. Others
6.5. Immunotherapy
6.5.1. Nivolumab
6.5.2. Pembrolizumab
6.6. Surgery
6.6.1. Gastrectomy
6.6.2. Gastrojejunostomy
6.6.3. Others
6.7. Others
7. GASTRIC CANCER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
7.1.2. Market Attractiveness Index, By Route of Administration
7.2. Injectable*
7.2.1. Introduction
7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Oral
8. GASTRIC CANCER TREATMENT MARKET, BY REGIONAL MARKET ANALYSIS AND GROWTH OPPORTUNITIES
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
8.1.2. Market Attractiveness Index, By Region
8.2. North America
8.2.1. Introduction
8.2.2. Key Region-Specific Dynamics
8.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
8.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
8.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
8.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
8.2.6.1. U.S.
8.2.6.2. Canada
8.2.6.3. Mexico
8.3. Europe
8.3.1. Introduction
8.3.2. Key Region-Specific Dynamics
8.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
8.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
8.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
8.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
8.3.6.1. Germany
8.3.6.2. UK
8.3.6.3. France
8.3.6.4. Spain
8.3.6.5. Italy
8.3.6.6. Rest of Europe
8.4. Asia-Pacific
8.4.1. Introduction
8.4.2. Key Region-Specific Dynamics
8.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
8.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
8.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
8.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
8.4.6.1. China
8.4.6.2. India
8.4.6.3. Japan
8.4.6.4. South Korea
8.4.6.5. Rest of Asia-Pacific
8.5. South America
8.5.1. Introduction
8.5.2. Key Region-Specific Dynamics
8.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
8.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
8.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
8.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
8.5.6.1. Brazil
8.5.6.2. Argentina
8.5.6.3. Rest of South America
8.6. Middle East and Africa
8.6.1. Introduction
8.6.2. Key Region-Specific Dynamics
8.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
8.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
8.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
9. COMPETITIVE LANDSCAPE AND MARKET POSITIONING
9.1. Competitive Overview and Key Market Players
9.2. Market Share Analysis and Positioning Matrix
9.3. Strategic Partnerships, Mergers & Acquisitions
9.4. Key Developments in Product Portfolios and Innovations
9.5. Company Benchmarking
10. COMPANY PROFILES
10.1. Merck & Co., Inc.*
10.1.1. Company Overview
10.1.2. Product Portfolio
10.1.2.1. Product Description
10.1.2.2. Product Key Performance Indicators (KPIs)
10.1.2.3. Historic and Forecasted Product Sales
10.1.2.4. Product Sales Volume
10.1.3. Financial Overview
10.1.3.1. Company Revenue’s
10.1.3.2. Geographical Revenue Shares
10.1.3.3. Revenue Forecasts
10.1.4. Key Developments
10.1.4.1. Mergers & Acquisitions
10.1.4.2. Key Product Development Activities
10.1.4.3. Regulatory Approvals, etc.
10.1.5. SWOT Analysis
10.2. Eli Lilly and Company
10.3. Genentech USA, Inc.
10.4. Pfizer Inc.
10.5. Astellas Pharma Inc.
10.6. Bristol-Myers Squibb Company
10.7. Blueprint Medicines Corporation
10.8. Daiichi Sankyo, Inc.
10.9. BeiGene, Ltd.
10.10. Ipsen Biopharmaceuticals Inc.
10.11. Taiho Oncology, Inc.
10.12. Deciphera Pharmaceuticals, LLC.
LIST NOT EXHAUSTIVE
11. ASSUMPTIONS AND RESEARCH METHODOLOGY
11.1. Data Collection Methods
11.2. Data Triangulation
11.3. Forecasting Techniques
11.4. Data Verification and Validation
12. APPENDIX
12.1. About Us and Services
12.2. Contact Us
1.1. Objectives of the Report
1.2. Report Coverage & Definitions
1.3. Report Scope
2. EXECUTIVE INSIGHTS AND KEY TAKEAWAYS
2.1. Market Highlights and Strategic Takeaways
2.2. Key Trends and Future Projections
2.3. Snippet by Cancer Type
2.4. Snippet by Treatment Type
2.5. Snippet by Route of Administration
2.6. Snippet by Region
3. DYNAMICS
3.1. Impacting Factors
3.1.1. Drivers
3.1.1.1. Advancements in Targeted Therapies
3.1.1.2. Expanding Clinical Trials and Research Investment
3.1.1.3. XX
3.1.2. Restraints
3.1.2.1. Side Effects and Safety Concerns
3.1.2.2. High Treatment Costs
3.1.2.3. XX
3.1.3. Opportunity
3.1.3.1. Advancements in Treatment Options
3.1.3.2. XX
3.1.4. Impact Analysis
4. STRATEGIC INSIGHTS AND INDUSTRY OUTLOOK
4.1. Market Leaders and Pioneers
4.1.1. Emerging Pioneers and Prominent Players
4.1.2. Established Leaders with Largest Marketing Brand
4.1.3. Market Leaders with Established Products
4.2. Latest Developments and Breakthroughs
4.3. Regulatory and Reimbursement Landscape
4.3.1. North America
4.3.2. Europe
4.3.3. Asia Pacific
4.3.4. Latin America
4.3.5. Middle East & Africa
4.4. Porter’s Five Forces Analysis
4.5. Supply Chain Analysis
4.6. Patent Analysis
4.7. SWOT Analysis
4.8. Pipeline Analysis
4.9. Epidemiology Analysis
4.10. Unmet Needs and Gaps
4.11. Recommended Strategies for Market Entry and Expansion
4.12. Scenario Analysis: Best-Case, Base-Case, and Worst-Case Forecasts
4.13. Pricing Analysis and Price Dynamics
4.14. Key Opinion Leaders
5. GASTRIC CANCER TREATMENT MARKET, BY CANCER TYPE
5.1. Introduction
5.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
5.1.2. Market Attractiveness Index, By Cancer Type
5.2. Non-Cardia (Distal) Stomach Cancer*
5.2.1. Introduction
5.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
5.3. Proximal Stomach Cancer
5.4. Diffuse Stomach Cancer
5.5. Lymphomas
5.6. Gastrointestinal Stromal Tumors
5.7. Carcinoid Tumors
5.8. Adenocarcinoma
5.9. Others
6. GASTRIC CANCER TREATMENT MARKET, BY TREATMENT TYPE
6.1. Introduction
6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
6.1.2. Market Attractiveness Index, By Treatment Type
6.2. Chemotherapy*
6.2.1. Introduction
6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
6.2.3. Capecitabine
6.2.4. Cisplatin
6.2.5. Docetaxel
6.2.6. Doxorubicin
6.2.7. Epirubicin
6.2.8. Fluorouracil (5-FU)
6.2.9. Irinotecan
6.2.10. Leucovorin
6.2.11. Oxaliplatin
6.2.12. Paclitaxel
6.2.13. Others
6.3. Radiation Therapy
6.4. Targeted Therapy
6.4.1. Ramucirumab
6.4.2. Regorafenib
6.4.3. Trastuzumab
6.4.4. Zolbetuximab
6.4.5. Others
6.5. Immunotherapy
6.5.1. Nivolumab
6.5.2. Pembrolizumab
6.6. Surgery
6.6.1. Gastrectomy
6.6.2. Gastrojejunostomy
6.6.3. Others
6.7. Others
7. GASTRIC CANCER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
7.1.2. Market Attractiveness Index, By Route of Administration
7.2. Injectable*
7.2.1. Introduction
7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Oral
8. GASTRIC CANCER TREATMENT MARKET, BY REGIONAL MARKET ANALYSIS AND GROWTH OPPORTUNITIES
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
8.1.2. Market Attractiveness Index, By Region
8.2. North America
8.2.1. Introduction
8.2.2. Key Region-Specific Dynamics
8.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
8.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
8.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
8.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
8.2.6.1. U.S.
8.2.6.2. Canada
8.2.6.3. Mexico
8.3. Europe
8.3.1. Introduction
8.3.2. Key Region-Specific Dynamics
8.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
8.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
8.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
8.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
8.3.6.1. Germany
8.3.6.2. UK
8.3.6.3. France
8.3.6.4. Spain
8.3.6.5. Italy
8.3.6.6. Rest of Europe
8.4. Asia-Pacific
8.4.1. Introduction
8.4.2. Key Region-Specific Dynamics
8.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
8.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
8.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
8.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
8.4.6.1. China
8.4.6.2. India
8.4.6.3. Japan
8.4.6.4. South Korea
8.4.6.5. Rest of Asia-Pacific
8.5. South America
8.5.1. Introduction
8.5.2. Key Region-Specific Dynamics
8.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
8.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
8.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
8.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
8.5.6.1. Brazil
8.5.6.2. Argentina
8.5.6.3. Rest of South America
8.6. Middle East and Africa
8.6.1. Introduction
8.6.2. Key Region-Specific Dynamics
8.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
8.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
8.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
9. COMPETITIVE LANDSCAPE AND MARKET POSITIONING
9.1. Competitive Overview and Key Market Players
9.2. Market Share Analysis and Positioning Matrix
9.3. Strategic Partnerships, Mergers & Acquisitions
9.4. Key Developments in Product Portfolios and Innovations
9.5. Company Benchmarking
10. COMPANY PROFILES
10.1. Merck & Co., Inc.*
10.1.1. Company Overview
10.1.2. Product Portfolio
10.1.2.1. Product Description
10.1.2.2. Product Key Performance Indicators (KPIs)
10.1.2.3. Historic and Forecasted Product Sales
10.1.2.4. Product Sales Volume
10.1.3. Financial Overview
10.1.3.1. Company Revenue’s
10.1.3.2. Geographical Revenue Shares
10.1.3.3. Revenue Forecasts
10.1.4. Key Developments
10.1.4.1. Mergers & Acquisitions
10.1.4.2. Key Product Development Activities
10.1.4.3. Regulatory Approvals, etc.
10.1.5. SWOT Analysis
10.2. Eli Lilly and Company
10.3. Genentech USA, Inc.
10.4. Pfizer Inc.
10.5. Astellas Pharma Inc.
10.6. Bristol-Myers Squibb Company
10.7. Blueprint Medicines Corporation
10.8. Daiichi Sankyo, Inc.
10.9. BeiGene, Ltd.
10.10. Ipsen Biopharmaceuticals Inc.
10.11. Taiho Oncology, Inc.
10.12. Deciphera Pharmaceuticals, LLC.
LIST NOT EXHAUSTIVE
11. ASSUMPTIONS AND RESEARCH METHODOLOGY
11.1. Data Collection Methods
11.2. Data Triangulation
11.3. Forecasting Techniques
11.4. Data Verification and Validation
12. APPENDIX
12.1. About Us and Services
12.2. Contact Us
LIST OF TABLES
Table 1 Global Gastric Cancer Treatment Market Value, By Cancer Type, 2025, 2029 & 2033 (US$ Billion)
Table 2 Global Gastric Cancer Treatment Market Value, By Treatment Type, 2025, 2029 & 2033 (US$ Billion)
Table 3 Global Gastric Cancer Treatment Market Value, By Route of Administration, 2025, 2029 & 2033 (US$ Billion)
Table 4 Global Gastric Cancer Treatment Market Value, By Region, 2025, 2029 & 2033 (US$ Billion)
Table 5 Global Gastric Cancer Treatment Market Value, By Cancer Type, 2025, 2029 & 2033 (US$ Billion)
Table 6 Global Gastric Cancer Treatment Market Value, By Cancer Type, 2022-2033 (US$ Billion)
Table 7 Global Gastric Cancer Treatment Market Value, By Treatment Type, 2025, 2029 & 2033 (US$ Billion)
Table 8 Global Gastric Cancer Treatment Market Value, By Treatment Type, 2022-2033 (US$ Billion)
Table 9 Global Gastric Cancer Treatment Market Value, By Route of Administration, 2025, 2029 & 2033 (US$ Billion)
Table 10 Global Gastric Cancer Treatment Market Value, By Route of Administration, 2022-2033 (US$ Billion)
Table 11 Global Gastric Cancer Treatment Market Value, By Region, 2025, 2029 & 2033 (US$ Billion)
Table 12 Global Gastric Cancer Treatment Market Value, By Region, 2022-2033 (US$ Billion)
Table 13 North America Gastric Cancer Treatment Market Value, By Cancer Type, 2022-2033 (US$ Billion)
Table 14 North America Gastric Cancer Treatment Market Value, By Treatment Type, 2022-2033 (US$ Billion)
Table 15 North America Gastric Cancer Treatment Market Value, By Route of Administration, 2022-2033 (US$ Billion)
Table 16 North America Gastric Cancer Treatment Market Value, By Country, 2022-2033 (US$ Billion)
Table 17 South America Gastric Cancer Treatment Market Value, By Cancer Type, 2022-2033 (US$ Billion)
Table 18 South America Gastric Cancer Treatment Market Value, By Treatment Type, 2022-2033 (US$ Billion)
Table 19 South America Gastric Cancer Treatment Market Value, By Route of Administration, 2022-2033 (US$ Billion)
Table 20 South America Gastric Cancer Treatment Market Value, By Country, 2022-2033 (US$ Billion)
Table 21 Europe Gastric Cancer Treatment Market Value, By Cancer Type, 2022-2033 (US$ Billion)
Table 22 Europe Gastric Cancer Treatment Market Value, By Treatment Type, 2022-2033 (US$ Billion)
Table 23 Europe Gastric Cancer Treatment Market Value, By Route of Administration, 2022-2033 (US$ Billion)
Table 24 Europe Gastric Cancer Treatment Market Value, By Country, 2022-2033 (US$ Billion)
Table 25 Asia-Pacific Gastric Cancer Treatment Market Value, By Cancer Type, 2022-2033 (US$ Billion)
Table 26 Asia-Pacific Gastric Cancer Treatment Market Value, By Treatment Type, 2022-2033 (US$ Billion)
Table 27 Asia-Pacific Gastric Cancer Treatment Market Value, By Route of Administration, 2022-2033 (US$ Billion)
Table 28 Asia-Pacific Gastric Cancer Treatment Market Value, By Country, 2022-2033 (US$ Billion)
Table 29 Middle East and Africa Gastric Cancer Treatment Market Value, By Cancer Type, 2022-2033 (US$ Billion)
Table 30 Middle East and Africa Gastric Cancer Treatment Market Value, By Treatment Type, 2022-2033 (US$ Billion)
Table 31 Middle East and Africa Gastric Cancer Treatment Market Value, By Route of Administration, 2022-2033 (US$ Billion)
Table 32 Middle East and Africa Gastric Cancer Treatment Market Value, By Country, 2022-2033 (US$ Billion)
Table 33 Merck & Co., Inc.: Overview
Table 34 Merck & Co., Inc.: Product Portfolio
Table 35 Merck & Co., Inc.: Key Developments
Table 36 Eli Lilly and Company: Overview
Table 37 Eli Lilly and Company: Product Portfolio
Table 38 Eli Lilly and Company: Key Developments
Table 39 Genentech USA, Inc.: Overview
Table 40 Genentech USA, Inc.: Product Portfolio
Table 41 Genentech USA, Inc.: Key Developments
Table 42 Pfizer Inc.: Overview
Table 43 Pfizer Inc.: Product Portfolio
Table 44 Pfizer Inc.: Key Developments
Table 45 Astellas Pharma Inc.: Overview
Table 46 Astellas Pharma Inc.: Product Portfolio
Table 47 Astellas Pharma Inc.: Key Developments
Table 48 Bristol-Myers Squibb Company: Overview
Table 49 Bristol-Myers Squibb Company: Product Portfolio
Table 50 Bristol-Myers Squibb Company: Key Developments
Table 51 Blueprint Medicines Corporation: Overview
Table 52 Blueprint Medicines Corporation: Product Portfolio
Table 53 Blueprint Medicines Corporation: Key Developments
Table 54 Daiichi Sankyo, Inc.: Overview
Table 55 Daiichi Sankyo, Inc.: Product Portfolio
Table 56 Daiichi Sankyo, Inc.: Key Developments
Table 57 BeiGene, Ltd.: Overview
Table 58 BeiGene, Ltd.: Product Portfolio
Table 59 BeiGene, Ltd.: Key Developments
Table 60 Ipsen Biopharmaceuticals Inc.: Overview
Table 61 Ipsen Biopharmaceuticals Inc.: Product Portfolio
Table 62 Ipsen Biopharmaceuticals Inc.: Key Developments
Table 63 Taiho Oncology, Inc.: Overview
Table 64 Taiho Oncology, Inc.: Product Portfolio
Table 65 Taiho Oncology, Inc.: Key Developments
Table 66 Deciphera Pharmaceuticals, LLC.: Overview
Table 67 Deciphera Pharmaceuticals, LLC.: Product Portfolio
Table 68 Deciphera Pharmaceuticals, LLC.: Key Developments
Table 1 Global Gastric Cancer Treatment Market Value, By Cancer Type, 2025, 2029 & 2033 (US$ Billion)
Table 2 Global Gastric Cancer Treatment Market Value, By Treatment Type, 2025, 2029 & 2033 (US$ Billion)
Table 3 Global Gastric Cancer Treatment Market Value, By Route of Administration, 2025, 2029 & 2033 (US$ Billion)
Table 4 Global Gastric Cancer Treatment Market Value, By Region, 2025, 2029 & 2033 (US$ Billion)
Table 5 Global Gastric Cancer Treatment Market Value, By Cancer Type, 2025, 2029 & 2033 (US$ Billion)
Table 6 Global Gastric Cancer Treatment Market Value, By Cancer Type, 2022-2033 (US$ Billion)
Table 7 Global Gastric Cancer Treatment Market Value, By Treatment Type, 2025, 2029 & 2033 (US$ Billion)
Table 8 Global Gastric Cancer Treatment Market Value, By Treatment Type, 2022-2033 (US$ Billion)
Table 9 Global Gastric Cancer Treatment Market Value, By Route of Administration, 2025, 2029 & 2033 (US$ Billion)
Table 10 Global Gastric Cancer Treatment Market Value, By Route of Administration, 2022-2033 (US$ Billion)
Table 11 Global Gastric Cancer Treatment Market Value, By Region, 2025, 2029 & 2033 (US$ Billion)
Table 12 Global Gastric Cancer Treatment Market Value, By Region, 2022-2033 (US$ Billion)
Table 13 North America Gastric Cancer Treatment Market Value, By Cancer Type, 2022-2033 (US$ Billion)
Table 14 North America Gastric Cancer Treatment Market Value, By Treatment Type, 2022-2033 (US$ Billion)
Table 15 North America Gastric Cancer Treatment Market Value, By Route of Administration, 2022-2033 (US$ Billion)
Table 16 North America Gastric Cancer Treatment Market Value, By Country, 2022-2033 (US$ Billion)
Table 17 South America Gastric Cancer Treatment Market Value, By Cancer Type, 2022-2033 (US$ Billion)
Table 18 South America Gastric Cancer Treatment Market Value, By Treatment Type, 2022-2033 (US$ Billion)
Table 19 South America Gastric Cancer Treatment Market Value, By Route of Administration, 2022-2033 (US$ Billion)
Table 20 South America Gastric Cancer Treatment Market Value, By Country, 2022-2033 (US$ Billion)
Table 21 Europe Gastric Cancer Treatment Market Value, By Cancer Type, 2022-2033 (US$ Billion)
Table 22 Europe Gastric Cancer Treatment Market Value, By Treatment Type, 2022-2033 (US$ Billion)
Table 23 Europe Gastric Cancer Treatment Market Value, By Route of Administration, 2022-2033 (US$ Billion)
Table 24 Europe Gastric Cancer Treatment Market Value, By Country, 2022-2033 (US$ Billion)
Table 25 Asia-Pacific Gastric Cancer Treatment Market Value, By Cancer Type, 2022-2033 (US$ Billion)
Table 26 Asia-Pacific Gastric Cancer Treatment Market Value, By Treatment Type, 2022-2033 (US$ Billion)
Table 27 Asia-Pacific Gastric Cancer Treatment Market Value, By Route of Administration, 2022-2033 (US$ Billion)
Table 28 Asia-Pacific Gastric Cancer Treatment Market Value, By Country, 2022-2033 (US$ Billion)
Table 29 Middle East and Africa Gastric Cancer Treatment Market Value, By Cancer Type, 2022-2033 (US$ Billion)
Table 30 Middle East and Africa Gastric Cancer Treatment Market Value, By Treatment Type, 2022-2033 (US$ Billion)
Table 31 Middle East and Africa Gastric Cancer Treatment Market Value, By Route of Administration, 2022-2033 (US$ Billion)
Table 32 Middle East and Africa Gastric Cancer Treatment Market Value, By Country, 2022-2033 (US$ Billion)
Table 33 Merck & Co., Inc.: Overview
Table 34 Merck & Co., Inc.: Product Portfolio
Table 35 Merck & Co., Inc.: Key Developments
Table 36 Eli Lilly and Company: Overview
Table 37 Eli Lilly and Company: Product Portfolio
Table 38 Eli Lilly and Company: Key Developments
Table 39 Genentech USA, Inc.: Overview
Table 40 Genentech USA, Inc.: Product Portfolio
Table 41 Genentech USA, Inc.: Key Developments
Table 42 Pfizer Inc.: Overview
Table 43 Pfizer Inc.: Product Portfolio
Table 44 Pfizer Inc.: Key Developments
Table 45 Astellas Pharma Inc.: Overview
Table 46 Astellas Pharma Inc.: Product Portfolio
Table 47 Astellas Pharma Inc.: Key Developments
Table 48 Bristol-Myers Squibb Company: Overview
Table 49 Bristol-Myers Squibb Company: Product Portfolio
Table 50 Bristol-Myers Squibb Company: Key Developments
Table 51 Blueprint Medicines Corporation: Overview
Table 52 Blueprint Medicines Corporation: Product Portfolio
Table 53 Blueprint Medicines Corporation: Key Developments
Table 54 Daiichi Sankyo, Inc.: Overview
Table 55 Daiichi Sankyo, Inc.: Product Portfolio
Table 56 Daiichi Sankyo, Inc.: Key Developments
Table 57 BeiGene, Ltd.: Overview
Table 58 BeiGene, Ltd.: Product Portfolio
Table 59 BeiGene, Ltd.: Key Developments
Table 60 Ipsen Biopharmaceuticals Inc.: Overview
Table 61 Ipsen Biopharmaceuticals Inc.: Product Portfolio
Table 62 Ipsen Biopharmaceuticals Inc.: Key Developments
Table 63 Taiho Oncology, Inc.: Overview
Table 64 Taiho Oncology, Inc.: Product Portfolio
Table 65 Taiho Oncology, Inc.: Key Developments
Table 66 Deciphera Pharmaceuticals, LLC.: Overview
Table 67 Deciphera Pharmaceuticals, LLC.: Product Portfolio
Table 68 Deciphera Pharmaceuticals, LLC.: Key Developments
LIST OF FIGURES
Figure 1 Global Gastric Cancer Treatment Market Value, 2022-2033 (US$ Billion)
Figure 2 Global Gastric Cancer Treatment Market Share, By Cancer Type, 2024 & 2033 (%)
Figure 3 Global Gastric Cancer Treatment Market Share, By Treatment Type, 2024 & 2033 (%)
Figure 4 Global Gastric Cancer Treatment Market Share, By Route of Administration, 2024 & 2033 (%)
Figure 5 Global Gastric Cancer Treatment Market Share, By Region, 2024 & 2033 (%)
Figure 6 Global Gastric Cancer Treatment Market Y-o-Y Growth, By Cancer Type, 2023-2033 (%)
Figure 7 Non-Cardia (Distal) Stomach Cancer Gastric Cancer Treatment Market Value, 2022-2033 (US$ Billion)
Figure 8 Proximal Stomach Cancer Gastric Cancer Treatment Market Value, 2022-2033 (US$ Billion)
Figure 9 Diffuse Stomach Cancer Gastric Cancer Treatment Market Value, 2022-2033 (US$ Billion)
Figure 10 Lymphomas Gastric Cancer Treatment Market Value, 2022-2033 (US$ Billion)
Figure 11 Gastrointestinal Stromal Tumors Gastric Cancer Treatment Market Value, 2022-2033 (US$ Billion)
Figure 12 Carcinoid Tumors Gastric Cancer Treatment Market Value, 2022-2033 (US$ Billion)
Figure 13 Adenocarcinoma Gastric Cancer Treatment Market Value, 2022-2033 (US$ Billion)
Figure 14 Others Gastric Cancer Treatment Market Value, 2022-2033 (US$ Billion)
Figure 15 Global Gastric Cancer Treatment Market Y-o-Y Growth, By Treatment Type, 2023-2033 (%)
Figure 16 Chemotherapy Treatment Type in Global Gastric Cancer Treatment Market Value, 2022-2033 (US$ Billion)
Figure 17 Radiation Therapy Treatment Type in Global Gastric Cancer Treatment Market Value, 2022-2033 (US$ Billion)
Figure 18 Targeted Therapy Treatment Type in Global Gastric Cancer Treatment Market Value, 2022-2033 (US$ Billion)
Figure 19 Immunotherapy Treatment Type in Global Gastric Cancer Treatment Market Value, 2022-2033 (US$ Billion)
Figure 20 Surgery Treatment Type in Global Gastric Cancer Treatment Market Value, 2022-2033 (US$ Billion)
Figure 21 Other Treatment Types in Global Gastric Cancer Treatment Market Value, 2022-2033 (US$ Billion)
Figure 22 Global Gastric Cancer Treatment Market Y-o-Y Growth, By Route of Administration, 2023-2033 (%)
Figure 23 Injectable Route of Administration in Global Gastric Cancer Treatment Market Value, 2022-2033 (US$ Billion)
Figure 24 Oral Route of Administration in Global Gastric Cancer Treatment Market Value, 2022-2033 (US$ Billion)
Figure 25 Global Gastric Cancer Treatment Market Y-o-Y Growth, By Region, 2023-2033 (%)
Figure 26 North America Gastric Cancer Treatment Market Value, 2022-2033 (US$ Billion)
Figure 27 North America Gastric Cancer Treatment Market Share, By Cancer Type, 2024 & 2033 (%)
Figure 28 North America Gastric Cancer Treatment Market Share, By Treatment Type, 2024 & 2033 (%)
Figure 29 North America Gastric Cancer Treatment Market Share, By Route of Administration, 2024 & 2033 (%)
Figure 30 North America Gastric Cancer Treatment Market Share, By Country, 2024 & 2033 (%)
Figure 31 South America Gastric Cancer Treatment Market Value, 2022-2033 (US$ Billion)
Figure 32 South America Gastric Cancer Treatment Market Share, By Cancer Type, 2024 & 2033 (%)
Figure 33 South America Gastric Cancer Treatment Market Share, By Treatment Type, 2024 & 2033 (%)
Figure 34 South America Gastric Cancer Treatment Market Share, By Route of Administration, 2024 & 2033 (%)
Figure 35 South America Gastric Cancer Treatment Market Share, By Country, 2024 & 2033 (%)
Figure 36 Europe Gastric Cancer Treatment Market Value, 2022-2033 (US$ Billion)
Figure 37 Europe Gastric Cancer Treatment Market Share, By Cancer Type, 2024 & 2033 (%)
Figure 38 Europe Gastric Cancer Treatment Market Share, By Treatment Type, 2024 & 2033 (%)
Figure 39 Europe Gastric Cancer Treatment Market Share, By Route of Administration, 2024 & 2033 (%)
Figure 40 Europe Gastric Cancer Treatment Market Share, By Country, 2024 & 2033 (%)
Figure 41 Asia-Pacific Gastric Cancer Treatment Market Value, 2022-2033 (US$ Billion)
Figure 42 Asia-Pacific Gastric Cancer Treatment Market Share, By Cancer Type, 2024 & 2033 (%)
Figure 43 Asia-Pacific Gastric Cancer Treatment Market Share, By Treatment Type, 2024 & 2033 (%)
Figure 44 Asia-Pacific Gastric Cancer Treatment Market Share, By Route of Administration, 2024 & 2033 (%)
Figure 45 Asia-Pacific Gastric Cancer Treatment Market Share, By Country, 2024 & 2033 (%)
Figure 46 Middle East and Africa Gastric Cancer Treatment Market Value, 2022-2033 (US$ Billion)
Figure 47 Middle East and Africa Gastric Cancer Treatment Market Share, By Cancer Type, 2024 & 2033 (%)
Figure 48 Middle East and Africa Gastric Cancer Treatment Market Share, By Treatment Type, 2024 & 2033 (%)
Figure 49 Middle East and Africa Gastric Cancer Treatment Market Share, By Route of Administration, 2024 & 2033 (%)
Figure 50 Merck & Co., Inc.: Financials
Figure 51 Eli Lilly and Company: Financials
Figure 52 Genentech USA, Inc.: Financials
Figure 53 Pfizer Inc.: Financials
Figure 54 Astellas Pharma Inc.: Financials
Figure 55 Bristol-Myers Squibb Company: Financials
Figure 56 Blueprint Medicines Corporation: Financials
Figure 57 Daiichi Sankyo, Inc.: Financials
Figure 58 BeiGene, Ltd.: Financials
Figure 59 Ipsen Biopharmaceuticals Inc.: Financials
Figure 60 Taiho Oncology, Inc.: Financials
Figure 61 Deciphera Pharmaceuticals, LLC.: Financials
Figure 1 Global Gastric Cancer Treatment Market Value, 2022-2033 (US$ Billion)
Figure 2 Global Gastric Cancer Treatment Market Share, By Cancer Type, 2024 & 2033 (%)
Figure 3 Global Gastric Cancer Treatment Market Share, By Treatment Type, 2024 & 2033 (%)
Figure 4 Global Gastric Cancer Treatment Market Share, By Route of Administration, 2024 & 2033 (%)
Figure 5 Global Gastric Cancer Treatment Market Share, By Region, 2024 & 2033 (%)
Figure 6 Global Gastric Cancer Treatment Market Y-o-Y Growth, By Cancer Type, 2023-2033 (%)
Figure 7 Non-Cardia (Distal) Stomach Cancer Gastric Cancer Treatment Market Value, 2022-2033 (US$ Billion)
Figure 8 Proximal Stomach Cancer Gastric Cancer Treatment Market Value, 2022-2033 (US$ Billion)
Figure 9 Diffuse Stomach Cancer Gastric Cancer Treatment Market Value, 2022-2033 (US$ Billion)
Figure 10 Lymphomas Gastric Cancer Treatment Market Value, 2022-2033 (US$ Billion)
Figure 11 Gastrointestinal Stromal Tumors Gastric Cancer Treatment Market Value, 2022-2033 (US$ Billion)
Figure 12 Carcinoid Tumors Gastric Cancer Treatment Market Value, 2022-2033 (US$ Billion)
Figure 13 Adenocarcinoma Gastric Cancer Treatment Market Value, 2022-2033 (US$ Billion)
Figure 14 Others Gastric Cancer Treatment Market Value, 2022-2033 (US$ Billion)
Figure 15 Global Gastric Cancer Treatment Market Y-o-Y Growth, By Treatment Type, 2023-2033 (%)
Figure 16 Chemotherapy Treatment Type in Global Gastric Cancer Treatment Market Value, 2022-2033 (US$ Billion)
Figure 17 Radiation Therapy Treatment Type in Global Gastric Cancer Treatment Market Value, 2022-2033 (US$ Billion)
Figure 18 Targeted Therapy Treatment Type in Global Gastric Cancer Treatment Market Value, 2022-2033 (US$ Billion)
Figure 19 Immunotherapy Treatment Type in Global Gastric Cancer Treatment Market Value, 2022-2033 (US$ Billion)
Figure 20 Surgery Treatment Type in Global Gastric Cancer Treatment Market Value, 2022-2033 (US$ Billion)
Figure 21 Other Treatment Types in Global Gastric Cancer Treatment Market Value, 2022-2033 (US$ Billion)
Figure 22 Global Gastric Cancer Treatment Market Y-o-Y Growth, By Route of Administration, 2023-2033 (%)
Figure 23 Injectable Route of Administration in Global Gastric Cancer Treatment Market Value, 2022-2033 (US$ Billion)
Figure 24 Oral Route of Administration in Global Gastric Cancer Treatment Market Value, 2022-2033 (US$ Billion)
Figure 25 Global Gastric Cancer Treatment Market Y-o-Y Growth, By Region, 2023-2033 (%)
Figure 26 North America Gastric Cancer Treatment Market Value, 2022-2033 (US$ Billion)
Figure 27 North America Gastric Cancer Treatment Market Share, By Cancer Type, 2024 & 2033 (%)
Figure 28 North America Gastric Cancer Treatment Market Share, By Treatment Type, 2024 & 2033 (%)
Figure 29 North America Gastric Cancer Treatment Market Share, By Route of Administration, 2024 & 2033 (%)
Figure 30 North America Gastric Cancer Treatment Market Share, By Country, 2024 & 2033 (%)
Figure 31 South America Gastric Cancer Treatment Market Value, 2022-2033 (US$ Billion)
Figure 32 South America Gastric Cancer Treatment Market Share, By Cancer Type, 2024 & 2033 (%)
Figure 33 South America Gastric Cancer Treatment Market Share, By Treatment Type, 2024 & 2033 (%)
Figure 34 South America Gastric Cancer Treatment Market Share, By Route of Administration, 2024 & 2033 (%)
Figure 35 South America Gastric Cancer Treatment Market Share, By Country, 2024 & 2033 (%)
Figure 36 Europe Gastric Cancer Treatment Market Value, 2022-2033 (US$ Billion)
Figure 37 Europe Gastric Cancer Treatment Market Share, By Cancer Type, 2024 & 2033 (%)
Figure 38 Europe Gastric Cancer Treatment Market Share, By Treatment Type, 2024 & 2033 (%)
Figure 39 Europe Gastric Cancer Treatment Market Share, By Route of Administration, 2024 & 2033 (%)
Figure 40 Europe Gastric Cancer Treatment Market Share, By Country, 2024 & 2033 (%)
Figure 41 Asia-Pacific Gastric Cancer Treatment Market Value, 2022-2033 (US$ Billion)
Figure 42 Asia-Pacific Gastric Cancer Treatment Market Share, By Cancer Type, 2024 & 2033 (%)
Figure 43 Asia-Pacific Gastric Cancer Treatment Market Share, By Treatment Type, 2024 & 2033 (%)
Figure 44 Asia-Pacific Gastric Cancer Treatment Market Share, By Route of Administration, 2024 & 2033 (%)
Figure 45 Asia-Pacific Gastric Cancer Treatment Market Share, By Country, 2024 & 2033 (%)
Figure 46 Middle East and Africa Gastric Cancer Treatment Market Value, 2022-2033 (US$ Billion)
Figure 47 Middle East and Africa Gastric Cancer Treatment Market Share, By Cancer Type, 2024 & 2033 (%)
Figure 48 Middle East and Africa Gastric Cancer Treatment Market Share, By Treatment Type, 2024 & 2033 (%)
Figure 49 Middle East and Africa Gastric Cancer Treatment Market Share, By Route of Administration, 2024 & 2033 (%)
Figure 50 Merck & Co., Inc.: Financials
Figure 51 Eli Lilly and Company: Financials
Figure 52 Genentech USA, Inc.: Financials
Figure 53 Pfizer Inc.: Financials
Figure 54 Astellas Pharma Inc.: Financials
Figure 55 Bristol-Myers Squibb Company: Financials
Figure 56 Blueprint Medicines Corporation: Financials
Figure 57 Daiichi Sankyo, Inc.: Financials
Figure 58 BeiGene, Ltd.: Financials
Figure 59 Ipsen Biopharmaceuticals Inc.: Financials
Figure 60 Taiho Oncology, Inc.: Financials
Figure 61 Deciphera Pharmaceuticals, LLC.: Financials
